**CONSORT 2010 checklist of information for PACE-UP randomised controlled trial 3-year follow-up**

Much of the detail relating to the PACE-UP trial is reported in the main PACE-UP trial outcome paper[1] and trial protocol paper[2]. Details are given here for clarity.

|  |  |  |  |
| --- | --- | --- | --- |
| Section/Topic | Item No | Standard Checklist item | Where information is provided in 3-year follow-up paper or other sources |
| Title & Abstract | 1a | Identification as a randomised trial in the title YES | Title |
| 1b | Structured summary of trial design, methods, results, & conclusions (see CONSORT checklist for abstracts table 2 below). YES | Abstract |
| Background and objectives | 2a | Scientific background and explanation of rationale YES | Introduction paragraphs 1 and 2. |
| 2b | Specific objectives or hypotheses YES | Introduction 3rd paragraph |
| Trial design | 3a | Description of trial design (such as parallel, factorial) including allocation ratio. YES | Details in main trial outcome paper[1] methods, study design. |
| 3b | Important changes to methods after trial commencement (such as eligibility criteria), with reasons YES | Details in main trial outcome paper[1] methods, statistical analyses. |
| Participants | 4a | Eligibility criteria for participants  YES | Details in main trial outcome paper[1] methods, study design participants and trial protocol paper[2]. |
| 4b | Settings and locations where the data were collected. YES | Details in main trial outcome paper[1] methods, study design & participants. |
| Interventions | 5 | The interventions for each group with sufficient details to allow replication, including how and when they were actually administered. YES | Details in main trial outcome paper[1] Figure S1 and trial protocol paper[2]. Also summarised in Table 1. |
| Outcomes | 6a | Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed YES | Methods, outcomes paragraph. |
| 6b | Any changes to trial outcomes after the trial commenced, with reasons | Not applicable |
| Sample size | 7a | How sample size was determined YES | Details in main trial outcome paper[1] Methods, statistical analysis and trial protocol paper[2] Methods, sample size. |
| 7b | When applicable, explanation of any interim analyses and stopping guidelines | Not applicable |
| Sequence generation | 8a | Method used to generate the random allocation sequence YES | Details in main trial outcome paper[1] Methods, randomisation and masking. |
| 8b | Type of randomisation; details of any restriction (such as blocking and block size) YES | Details in main trial outcome paper[1] Methods, randomisation and masking. |
| Allocation concealment mechanism | 9 | Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned. YES | Details in main trial outcome paper[1] Methods, randomisation and masking. |
| Implementation | 10 | Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions. YES | Details in main trial outcome paper[1] Methods, randomisation and masking. |
| Blinding | 11a | If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how. YES | Details in main trial outcome paper[1] Methods, randomisation and masking. |
| 11b | If relevant, description of the similarity of interventions. YES | Summarised in Table 1. |
| Statistical methods | 12a | Statistical methods used to compare groups for primary and secondary outcomes YES | Details in main trial outcome paper[1] Methods, statistical analysis |
| 12b | Methods for additional analyses, such as subgroup analyses and adjusted analyses. YES | Details in main trial outcome paper[1] Methods, statistical analysis |
| Participant flow (a diagram is strongly recommended) | 13a | For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome YES | Figure 1a (CONSORT diagram for 3-year follow-up) |
| 13b | For each group, losses and exclusions after randomisation, together with reasons YES | Figure 1a (CONSORT diagram for 3-year follow-up) |
| Recruitment | 14a | Dates defining the periods of recruitment and follow-up YES | For main trial see trial outcome paper[1] Methods, study design and participants.  For 3-year follow-up see Methods, PACE-UP 3-year follow-up. |
| 14b | Why the trial ended or was stopped | Not applicable |
| Baseline data | 15 | A table showing baseline demographic and clinical characteristics for each group YES | Details in main trial outcome paper[1] (Table 1). |
| Numbers analysed | 16 | For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups YES | CONSORT diagram Figure 1a |
| Outcomes and estimation | 17a | For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval). YES | Results, Table 2 and Figure 2. |
| 17b | For binary outcomes, presentation of both absolute and relative effect sizes is recommended | Not a binary outcome |
| Ancillary analyses | 18 | Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory. YES | Sensitivity analyses assessed the effect of missing data at 3 years, (Methods, statistical analysis and results Table 3 & S2 Figure). |
| Harms | 19 | All important harms or unintended effects in each group (for specific guidance see CONSORT for harms) YES | For main trial see trial outcome paper[1] Results, Table 4. |
| Limitations | 20 | Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses.  YES | Details in main trial outcome paper[1] Discussion, study strengths and limitations.  Details relating to 3-year follow-up, Discussion (paragraph on strengths and limitations). |
| Generalisability | 21 | Generalisability (external validity, applicability) of the trial findings. YES | Details in main trial outcome paper[1]  Relating to 3-year follow-up, Discussion, implications. |
| Interpretation | 22 | Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence. YES | Relating to 3-year follow-up, Discussion, comparison with other studies. |
| Registration | 23 | Registration number and name of trial registry YES | At end of abstract. |
| Protocol | 24 | Where the full trial protocol can be accessed, if available  YES | Published trial protocol paper[2]. Open access online journal & available on PACE-UP website [www.paceup.sgul.ac.uk](http://www.paceup.sgul.ac.uk) For 3-year follow-up details, protocol approved by ethics available as S1 Text. |
| Funding | 25 | Sources of funding and other support (such as supply of drugs), role of funders YES | Included in PLoS Med online funding declaration submission |

**Table 2: CONSORT checklist for abstracts**

|  |  |  |
| --- | --- | --- |
| Item | Standard Checklist item | Included in main trial outcomes paper abstract (S1 Text)[1] |
| Title | Identification of study as randomised. | YES |
| Trial design | Description of the trial design (e.g. parallel, cluster, non-inferiority) | YES |
| Methods |  |  |
| Participants | Eligibility criteria for participants and the settings where the data were collected. | YES |
| Interventions | Interventions intended for each group. | YES |
| Objective | Specific objective or hypothesis. | YES |
| Outcome | Clearly defined primary outcome for this report. | YES |
| Randomization | How participants were allocated to interventions. | YES |
| Blinding (masking) | Whether or not participants, care givers, and those assessing the outcomes were blinded to group assignment. | YES |
| Results |  |  |
| Numbers randomized | Number of participants randomized to each group. | YES |
| Numbers analysed | Number of participants analysed in each group. | YES |
| Outcome | For the primary outcome, a result for each group and the estimated effect size and its precision. | YES |
| Harms | Important adverse events or side effects  NO, this was not a primary or secondary  outcome, but they are reported in paper. | NO |
| Conclusions | General interpretation of the results. | YES |
| Trial registration | Registration number and name of trial register. | YES |
| Funding | Source of funding. | YES |

**References:**

1. Harris T, Kerry SM, Limb ES, Victor CR, Iliffe S, Ussher M, et al. Effect of a Primary Care Walking Intervention with and without Nurse Support on Physical Activity Levels in 45- to 75-Year-Olds: The Pedometer And Consultation Evaluation (PACE-UP) Cluster Randomised Clinical Trial. PLoS Med. 2017;14(1):e1002210.

2. Harris T, Kerry SM, Victor CR, Shah SM, Iliffe S, Ussher M, et al. PACE-UP (Pedometer and consultation evaluation - UP) - a pedometer-based walking intervention with and without practice nurse support in primary care patients aged 45-75 years: study protocol for a randomised controlled trial. Trials. 2013;14:418.